Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.

Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, Sharpless NE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):653-63. doi: 10.1111/pcmr.12238. Epub 2014 Apr 7.

2.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W.

Oncologist. 2014 Jun;19(6):616-22. doi: 10.1634/theoncologist.2014-0011. Epub 2014 May 5.

3.

ERBB4 mutation analysis: emerging molecular target for melanoma treatment.

Lau C, Killian KJ, Samuels Y, Rudloff U.

Methods Mol Biol. 2014;1102:461-80. doi: 10.1007/978-1-62703-727-3_24.

PMID:
24258993
4.

A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.

Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z.

Mol Cancer Ther. 2014 Jul;13(7):1918-28. doi: 10.1158/1535-7163.MCT-13-0804. Epub 2014 Apr 22.

5.

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.

Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG.

Semin Cutan Med Surg. 2012 Dec;31(4):267-73. doi: 10.1016/j.sder.2012.07.007.

PMID:
23174497
6.

A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.

Dutton-Regester K, Irwin D, Hunt P, Aoude LG, Tembe V, Pupo GM, Lanagan C, Carter CD, O'Connor L, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, Hayward NK.

Mol Cancer Ther. 2012 Apr;11(4):888-97. doi: 10.1158/1535-7163.MCT-11-0676. Epub 2012 Mar 1.

7.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

8.

High-throughput sequencing of the melanoma genome.

Kunz M, Dannemann M, Kelso J.

Exp Dermatol. 2013 Jan;22(1):10-7. doi: 10.1111/exd.12054. Epub 2012 Nov 22.

9.

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W.

Clin Cancer Res. 2013 Dec 15;19(24):6696-702. doi: 10.1158/1078-0432.CCR-13-1746.

10.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.

11.

Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes.

Luscan A, Just PA, Briand A, Burin des Roziers C, Goussard P, Nitschké P, Vidaud M, Avril MF, Terris B, Pasmant E.

Br J Ophthalmol. 2015 Apr;99(4):437-9. doi: 10.1136/bjophthalmol-2014-305371. Epub 2014 Oct 31.

PMID:
25361747
12.

Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.

Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, Hemminki K, Schadendorf D, Kumar R.

Genes Chromosomes Cancer. 2010 Aug;49(8):733-45. doi: 10.1002/gcc.20785.

PMID:
20544847
13.

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.

Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R, Merkelbach-Bruse S.

BMC Cancer. 2014 Jan 10;14:13. doi: 10.1186/1471-2407-14-13.

14.

Molecular and genetic diversity in the metastatic process of melanoma.

Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Törngren T, Kvist A, Nodin B, Olsson E, Häkkinen J, Jirström K, Staaf J, Lundgren L, Olsson H, Ingvar C, Gruvberger-Saal SK, Saal LH, Jönsson G.

J Pathol. 2014 May;233(1):39-50. doi: 10.1002/path.4318. Epub 2014 Jan 27.

15.

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y.

Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26.

16.

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.

Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ.

Diagn Mol Pathol. 2012 Mar;21(1):1-8. doi: 10.1097/PDM.0b013e31823b216f.

PMID:
22306669
17.

What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing.

Wilson MA, Morrissette JJ, McGettigan S, Roth D, Elder D, Schuchter LM, Daber RD.

Cancer Genet. 2014 Jun;207(6):272-5. doi: 10.1016/j.cancergen.2014.06.022. Epub 2014 Jun 18.

PMID:
25178945
18.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
19.

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA.

Cancer Discov. 2012 Jan;2(1):82-93. doi: 10.1158/2159-8290.CD-11-0184. Epub 2011 Nov 7.

20.

Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling.

Cifola I, Pietrelli A, Consolandi C, Severgnini M, Mangano E, Russo V, De Bellis G, Battaglia C.

PLoS One. 2013 May 21;8(5):e63597. doi: 10.1371/journal.pone.0063597. Print 2013.

Items per page

Supplemental Content

Write to the Help Desk